Epidemiology
Elevated Lp(a) brought more cardiovascular events over 5 years and real psychosocial distress in Germany's ELITE cohort study (Lipids Health Dis 2025)
Original title: Cardiovascular endpoints and psychosocial challenges of lipoprotein(a) of 5726 participants in the ELITE-study over 5 years
The ELITE study, a prospective interventional cohort in north-western Germany, compared 3,241 participants with normal Lp(a) (mean 16.4 nmol/L) against 841 with elevated Lp(a) of 75 nmol/L or above (mean 154.8 nmol/L, comparable age around 53 and roughly 49% female in both groups), following participants for a mean 4.4 years with regular cardiovascular risk factor assessment and personalised written prevention recommendations. Combined cardiovascular endpoints (coronary heart disease, stroke, heart failure, peripheral artery disease, carotid stenosis, atrial fibrillation) occurred significantly more often in the elevated-Lp(a) group (P < 0.001), despite similar risk factor profiles apart from higher baseline LDL-C; lipid-lowering therapy use in that group rose from 12% to 23% after intervention. Most participants with elevated Lp(a) had been unaware of their level, and around 40% reported concern or anxiety after learning it, a dimension surveyed here for the first time. The authors argue this confirms Lp(a)'s causal contribution to cardiovascular morbidity and highlights an unmet need for structured education and counselling around the psychosocial burden of an Lp(a) diagnosis.
Original abstract
Background: Lipoprotein(a) [Lp(a)] is a known independent risk factor for cardiovascular disease, yet awareness and management remain limited. The psychosocial implications of elevated Lp(a)-levels have been poorly characterized.
Objectives: To compare cardiovascular outcomes and cardiovascular risk factor (CVRF) modification in individuals with normal vs. elevated Lp(a) levels, and to assess the impact of individualized prevention recommendations. For the first time, the individual psychological stress caused by Lp(a) is being surveyed.
Methods: The ELITE study is a prospective, interventional cohort study conducted in north-western Germany. Participants were regularly assessed for CVRFs, including Lp(a), hypertension, dyslipidemia, diabetes mellitus, weight, nicotine - as well as lipoprotein (a), physical activity, dietary habits, depression and stress. They received written, personalized prevention recommendations. Follow-up averaged 4.4 years. Two groups were analyzed: Group 1 (Gr1, n=3,241) with normal Lp(a), and Group 2 (Gr2, n=841) with elevated Lp(a ≥75 nmol/l).
Results: Gr2 (mean Lp(a) 154.8 nmol/l) and Gr1 (mean Lp(a) 16.4 nmol/l) were comparable in age (~53 years) and sex distribution (~49% female). Most participants with elevated Lp(a) were previously unaware of their levels; 30% were referred to specialists, and ~40% reported concern or anxiety. Combined cardiovascular endpoints (CHD, stroke, heart failure, PAD, carotid stenosis, AF) occurred significantly more often in Gr2 (p<0.001), despite similar CVRF profiles, except for higher baseline LDL-C in Gr2 (p<0.001). Hypertension (61%) and physical inactivity (57%) were the most prevalent CVRFs. Personalized prevention measures led to significant improvements in blood pressure, LDL-C, smoking, physical activity, and weight in both groups. Lipid-lowering therapy improved markedly in Gr2 (12% to 23%).
Conclusions: Elevated Lp(a) is associated with a significantly higher rate of cardiovascular events, independent of traditional CVRFs. This confirms a causal role of Lp(a) in CV morbidity. Personalized written prevention recommendations improved CVRFs across both groups, though further optimization is needed. Notably, elevated Lp(a) also imposes a psychosocial burden, underlining the need for enhanced education, counseling, and clinical pathways.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.